Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 541: What percentage of a drug is eliminated after four half-lives in first-order kinetics?

A. 84.00%
B. 93.75% (Correct Answer)
C. 80.00%
D. 5.00%

Explanation: ***93.75%*** - In **first-order kinetics**, a constant **fraction** (not amount) of the drug is eliminated per unit time - After 1 half-life: 50% eliminated (50% remains) - After 2 half-lives: 75% eliminated (25% remains) - After 3 half-lives: 87.5% eliminated (12.5% remains) - After 4 half-lives: **93.75% eliminated** (6.25% remains) *84.00%* - This represents approximately 16% remaining drug - Would occur between the 2nd and 3rd half-lives, not at exactly 4 half-lives - Does not correspond to the mathematical progression of first-order kinetics *80.00%* - This represents 20% remaining drug - Does not correspond to any whole number of half-lives - Falls between 2 half-lives (75% eliminated) and 3 half-lives (87.5% eliminated) *5.00%* - This suggests only 5% elimination with 95% drug remaining - Would occur very early in the elimination process, less than 1 half-life - Fundamentally incorrect for 4 half-lives where 93.75% should be eliminated

Question 542: What is the definition of bioavailability?

A. Ratio of Area of oral to Area of IV (Correct Answer)
B. Ratio of Area of IV to Area of oral
C. Ratio of Area of IV to Area of oral multiplied by 100
D. Ratio of Area of oral to Area of IV multiplied by 100

Explanation: ***Ratio of Area of oral to Area of IV*** - **Bioavailability (F)** is defined as the **fraction** of an administered dose of unchanged drug that reaches the systemic circulation - It is calculated as: **F = AUC_oral / AUC_IV** (when doses are equal) - This gives a value between **0 and 1** (e.g., F = 0.75 means 75% bioavailable) - This is the **standard pharmacological definition** as per Goodman & Gilman and other authoritative texts *Ratio of Area of oral to Area of IV multiplied by 100* - This expresses bioavailability as a **percentage** rather than a fraction - While bioavailability can be *communicated* as a percentage (e.g., "75% bioavailable"), the formal definition is as a **fraction** - Multiplying by 100 is a conversion for expression, not part of the core definition *Ratio of Area of IV to Area of oral* - This is the **inverse ratio** of bioavailability - It would give values **greater than 1** for drugs with incomplete absorption - Does not represent the fraction of oral dose reaching systemic circulation *Ratio of Area of IV to Area of oral multiplied by 100* - This combines two errors: **inverse ratio** and percentage conversion - Would yield values >100% for drugs with bioavailability <1 - Completely incorrect definition of bioavailability

Question 543: Which of the following factors does not affect the action of lignocaine?

A. PH at the site of injection
B. Vasoconstrictor in the L.A solution
C. Blood flow at the site of injection
D. Action of cholinesterase at the site of injection (Correct Answer)

Explanation: ***Action of cholinesterase at the site of injection*** - **Lidocaine** is an **amide-type local anesthetic** and is primarily metabolized by the liver, not by cholinesterases. - Cholinesterases are responsible for metabolizing **ester-type local anesthetics** (e.g., procaine) and acetylcholine. *PH at the site of injection* - The **pH** at the injection site significantly affects lignocaine's action, as its **unionized form** (which is favored in alkaline pH) is essential for penetrating nerve membranes. - In acidic environments (e.g., infected tissue), less unionized lignocaine is available, leading to reduced efficacy. *Blood flow at the site of injection* - **Increased blood flow** at the site of injection can accelerate the systemic absorption of lignocaine, thereby reducing its duration of action at the nerve. - **Decreased blood flow** can prolong its local action, but also increase the risk of systemic toxicity if absorption is very slow. *Vasoconstrictor in the L.A solution* - The addition of a **vasoconstrictor** (e.g., epinephrine) slows the systemic absorption of lignocaine from the injection site. - This **prolongs the duration of action** and reduces the risk of systemic toxicity by keeping the anesthetic concentrated at the target nerves.

Question 544: Which among the following drugs produces a dose ceiling effect?

A. Alfentanil (short-acting opioid)
B. Remifentanil (ultra-short-acting opioid)
C. Morphine (full agonist)
D. Buprenorphine (partial agonist) (Correct Answer)

Explanation: ***Buprenorphine*** - **Buprenorphine** is a **partial opioid agonist**, meaning its effects, particularly respiratory depression, plateau at higher doses. - This **ceiling effect** means that increasing the dose beyond a certain point does not produce additional analgesic or respiratory depressant effects, making it safer in terms of overdose risk. *Alfentanil (short-acting opioid)* - **Alfentanil** is a **full opioid agonist** that does not exhibit a dose ceiling effect; its effects, including respiratory depression, continue to increase with higher doses. - It is known for its **rapid onset and short duration of action**, making it suitable for brief procedural sedation. *Remifentanil (ultra-short-acting opioid)* - **Remifentanil** is an **ultra-short-acting full opioid agonist** with no dose ceiling effect, meaning its pharmacological effects escalate with increasing doses. - Its unique **esterase metabolism** allows for very rapid offset, making it ideal for maintaining precise anesthetic depth. *Morphine (full agonist)* - **Morphine** is a **full opioid agonist** that does not have a dose ceiling effect; its analgesic and respiratory depressant effects continue to increase as the dose is raised. - It is a **prototypical opioid** often used for moderate to severe pain and is associated with significant dose-dependent side effects.

Question 545: What is the main barrier for the diffusion of local anesthetic?

A. Epineurium
B. Endoneurium
C. Perineurium (Correct Answer)
D. None of the options.

Explanation: **Perineurium** - The **perineurium** is the main barrier to the diffusion of local anesthetics, forming a tight sheath that surrounds fascicles of nerve fibers. - Its **tight junctions** between cells create a blood-nerve barrier, restricting the passage of substances into the nerve. *Epineurium* - The **epineurium** is the outermost connective tissue layer covering the entire nerve, which is relatively loose and offers little resistance to anesthetic diffusion. - Its main function is to provide **protection** and cushioning to the nerve, rather than acting as a diffusion barrier. *Endoneurium* - The **endoneurium** is the delicate connective tissue that surrounds individual nerve fibers within a fascicle. - While it provides structural support, it is **highly permeable** and does not significantly impede the diffusion of local anesthetics. *None of the options.* - This option is incorrect because the **perineurium** is a well-established anatomical barrier for local anesthetic diffusion.

Question 546: What is the mechanism by which standard doses of lidocaine can lead to cardiac or central nervous system toxicity in patients with circulatory failure?

A. Histamine receptors in the brain and heart are activated during circulatory failure.
B. There is a sudden release of catecholamines in the brain and heart during circulatory failure.
C. Lidocaine is metabolized in the liver, but this does not lead to a toxic metabolite.
D. Lidocaine concentration can increase in well-perfused tissues such as the brain and heart during circulatory failure. (Correct Answer)

Explanation: ***Lidocaine concentration can increase in well-perfused tissues such as the brain and heart during circulatory failure.*** - In states of **circulatory failure**, tissues with high blood flow like the brain and heart receive a relatively larger proportion of the distributed drug. This can lead to increased lidocaine concentrations in these vital organs. - Reduced **hepatic blood flow** in circulatory failure means less lidocaine is metabolized, thus increasing its availability for distribution and subsequent accumulation in well-perfused areas, leading to toxicity even at standard doses. *Histamine receptors in the brain and heart are activated during circulatory failure.* - Activation of **histamine receptors** in the brain and heart is not a primary mechanism for lidocaine toxicity in circulatory failure. - Lidocaine's toxic effects primarily stem from its action as a **sodium channel blocker** rather than through histamine pathways. *There is a sudden release of catecholamines in the brain and heart during circulatory failure.* - While circulatory failure can trigger **catecholamine release**, this mechanism does not directly explain how lidocaine itself becomes toxic at standard doses. - **Catecholamine release** might exacerbate some cardiac issues but is not the direct cause of lidocaine's neurotoxicity or cardiotoxicity in this context. *Lidocaine is metabolized in the liver, but this does not lead to a toxic metabolite.* - While lidocaine is primarily metabolized by the **liver**, its metabolite, **monoethylglycinexylidide (MEGX)**, *is* pharmacologically active and can contribute to toxicity, particularly CNS effects. - The reduced hepatic blood flow and metabolic capacity during circulatory failure lead to **decreased clearance** of the parent drug and its active metabolites, thus increasing their concentrations and contributing to toxicity.

Question 547: Which of the following drugs is a prodrug that, after oral administration, is converted to an active agent, penciclovir?

A. Acyclovir
B. Ganciclovir
C. Famciclovir (Correct Answer)
D. Fomivirsen

Explanation: ***Famciclovir*** - **Famciclovir** is an oral prodrug of **penciclovir**. After absorption, it undergoes first-pass metabolism to penciclovir, its active antiviral form. - **Penciclovir** is effective against **herpes simplex virus (HSV)** and **varicella-zoster virus (VZV)**, inhibiting viral DNA polymerase. *Acyclovir (active drug)* - **Acyclovir** is an active antiviral drug and is well-known for its use directly as an antiviral, not as a prodrug for penciclovir. - Although it is also converted to an active triphosphate form inside infected cells, its structure is distinct from penciclovir. *Ganciclovir (for CMV infections)* - **Ganciclovir** is an antiviral drug primarily used to treat and prevent **cytomegalovirus (CMV)** infections. - It is an active nucleoside analog itself, similar to acyclovir, and is not a prodrug for penciclovir. *Fomivirsen (used for CMV retinitis)* - **Fomivirsen** is an antisense oligonucleotide used specifically for the treatment of **CMV retinitis** in AIDS patients. - Its mechanism of action involves binding to CMV mRNA to inhibit viral protein synthesis, and it is unrelated to penciclovir.

Question 548: Which of the following drugs is least likely to cross the blood-placental barrier?

A. Atropine
B. Physostigmine
C. Hyoscine hydrobromide
D. Glycopyrrolate (Correct Answer)

Explanation: ***Glycopyrrolate*** - Glycopyrrolate is a **quaternary ammonium compound**, meaning it is highly ionized and has a low lipid solubility. - Its **polar nature** and **larger molecular weight** restrict its ability to readily cross lipid membranes, including the blood-placental barrier. *Atropine* - **Atropine** is a tertiary amine, making it a **lipid-soluble** compound. - Its lipid solubility allows it to **easily cross the blood-placental barrier** and affect the fetus. *Physostigmine* - Physostigmine is also a **tertiary amine** and is relatively **lipid-soluble**. - This property enables it to **readily cross lipid barriers** such as the blood-placental barrier and the blood-brain barrier. *Hyoscine hydrobromide* - **Hyoscine hydrobromide** (scopolamine) is a **tertiary amine** and highly **lipid-soluble**. - Its high lipid solubility allows for its **easy passage across the blood-placental barrier** and into the fetal circulation.

Question 549: All of the following statements regarding the bioavailability of a drug are true except which one?

A. It is a fraction of administered drug that reaches the systemic circulation in unchanged form
B. Bioavailability can be determined from plasma concentration or urinary excretion data.
C. Low oral availability always and necessarily means poor absorption (Correct Answer)
D. Bioavailability of an orally administered drug can be calculated by comparing the Area Under Curve after oral and intravenous administration

Explanation: ***Low oral availability always and necessarily means poor absorption*** - While **poor absorption** can lead to low oral availability, it is not the *only* reason; extensive **first-pass metabolism** in the liver or gut wall can also significantly reduce the fraction of the drug reaching systemic circulation even if absorption is good. - The phrase "always and necessarily" makes this statement incorrect, as it overlooks other critical factors like **hepatic metabolism** that influence bioavailability. *It is a fraction of administered drug that reaches the systemic circulation in unchanged form* - This is the standard definition of **bioavailability**, representing the proportion of the drug that enters the systemic circulation and is available to produce its pharmacological effect. - The drug must reach the systemic circulation **unchanged** to be considered bioavailable, as metabolites may have different or no pharmacological activity. *Bioavailability can be determined from plasma concentration or urinary excretion data.* - **Plasma concentration-time curves** (specifically the Area Under the Curve or AUC) directly reflect the amount of drug that has entered the systemic circulation over time. - For drugs primarily excreted unchanged in urine, **cumulative urinary excretion data** can also be used to estimate systemic availability. *Bioavailability of an orally administered drug can be calculated by comparing the Area Under Curve after oral and intravenous administration* - This is the most common method for calculating **absolute bioavailability**, as intravenous (IV) administration bypasses absorption and first-pass metabolism, providing 100% bioavailability. - The formula used is (AUC oral / Dose oral) / (AUC IV / Dose IV), which effectively compares the **extent of systemic exposure** from oral administration to that of IV administration.

Question 550: Which of the following statements is true about first-order kinetics?

A. The half-life increases with an increase in dose.
B. The rate of elimination is proportional to the plasma concentration. (Correct Answer)
C. A constant amount is eliminated in unit time.
D. The elimination follows zero-order kinetics at therapeutic doses.

Explanation: ***The rate of elimination is proportional to the plasma concentration.*** - In **first-order kinetics**, a **constant fraction** of the drug is eliminated per unit of time, meaning that the higher the plasma concentration, the faster the elimination rate. - This principle ensures that the drug concentration decreases exponentially over time, as the amount eliminated is always a percentage of the remaining drug. - The rate equation is: dC/dt = -kC, where the rate is directly proportional to concentration. *The half-life increases with an increase in dose.* - This statement is incorrect because, for **first-order kinetics**, the **half-life remains constant** regardless of the dose or the initial concentration of the drug. - The time it takes for the plasma concentration to halve is independent of the initial amount. *The elimination follows zero-order kinetics at therapeutic doses.* - This is incorrect. **First-order kinetics** is the most common pattern for drug elimination at **therapeutic doses**. - **Zero-order kinetics** occurs when elimination mechanisms become **saturated**, typically at very high doses (e.g., phenytoin, ethanol, aspirin at high doses). *A constant amount is eliminated in unit time.* - This describes **zero-order kinetics**, where the elimination process is saturated, and the body eliminates a fixed amount of drug per unit of time, regardless of the plasma concentration. - In **first-order kinetics**, a **constant *fraction*** (not amount) is eliminated per unit time.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free